Fatigue in children who have recently completed treatment for acute lymphoblastic leukemia: a longitudinal study
Background This study examined fatigue in patients treated for childhood acute lymphoblastic leukemia (ALL) over a 2-year period (3- to 27-months post-treatment completion), from the perspective of children and parent caregivers, compared to a healthy comparison group. Methods Eighty-three patients (4–16 years at enrolment) and their parents, reported on the child’s fatigue using the Pediatric Quality of Life Inventory– Multidimensional Fatigue Scale (PedsQL-MFS), at 3- 15- and 27-months post-treatment completion, and 53 healthy children and their parents reported on fatigue across the same timepoints. Results Parent proxy-reporting showed that parents of ALL patients reported more total fatigue than parents of the comparison group at all time points, with all subscales elevated (general, cognitive, and sleep/rest fatigue). In contrast, patient self-report of fatigue over this period differed from the comparison children for the general fatigue subscale only. Self-reported total fatigue was worse than the comparison group at the 27-month timepoint, with cognitive and sleep/rest fatigue symptoms contributing to this difference. Expected improvements in fatigue over time were not evident in either patient or parent report and no demographic risk factors were identified. Parents and children from both groups reported significantly more fatigue at all time points compared to commonly utilised normative population data. Conclusions Patients treated for childhood ALL are impacted by fatigue symptoms in the post-treatment and early survivorship period. These findings highlight that patients in the 2-years following treatment require increased symptom surveillance and may benefit particularly from interventions that target cognitive and sleep/rest fatigue..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Health and quality of life outcomes - 22(2024), 1 vom: 22. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walsh, S. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Crown 2024 |
|---|
| doi: |
10.1186/s12955-024-02241-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055257593 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055257593 | ||
| 003 | DE-627 | ||
| 005 | 20240323064752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12955-024-02241-2 |2 doi | |
| 035 | |a (DE-627)SPR055257593 | ||
| 035 | |a (SPR)s12955-024-02241-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Walsh, S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fatigue in children who have recently completed treatment for acute lymphoblastic leukemia: a longitudinal study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Crown 2024 | ||
| 520 | |a Background This study examined fatigue in patients treated for childhood acute lymphoblastic leukemia (ALL) over a 2-year period (3- to 27-months post-treatment completion), from the perspective of children and parent caregivers, compared to a healthy comparison group. Methods Eighty-three patients (4–16 years at enrolment) and their parents, reported on the child’s fatigue using the Pediatric Quality of Life Inventory– Multidimensional Fatigue Scale (PedsQL-MFS), at 3- 15- and 27-months post-treatment completion, and 53 healthy children and their parents reported on fatigue across the same timepoints. Results Parent proxy-reporting showed that parents of ALL patients reported more total fatigue than parents of the comparison group at all time points, with all subscales elevated (general, cognitive, and sleep/rest fatigue). In contrast, patient self-report of fatigue over this period differed from the comparison children for the general fatigue subscale only. Self-reported total fatigue was worse than the comparison group at the 27-month timepoint, with cognitive and sleep/rest fatigue symptoms contributing to this difference. Expected improvements in fatigue over time were not evident in either patient or parent report and no demographic risk factors were identified. Parents and children from both groups reported significantly more fatigue at all time points compared to commonly utilised normative population data. Conclusions Patients treated for childhood ALL are impacted by fatigue symptoms in the post-treatment and early survivorship period. These findings highlight that patients in the 2-years following treatment require increased symptom surveillance and may benefit particularly from interventions that target cognitive and sleep/rest fatigue. | ||
| 650 | 4 | |a ALL |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Leukemia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fatigue |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pediatric |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oncology |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mulraney, M. |4 aut | |
| 700 | 1 | |a McCarthy, M.C. |4 aut | |
| 700 | 1 | |a De Luca, Cinzia R. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health and quality of life outcomes |d BioMed Central, 2003 |g 22(2024), 1 vom: 22. März |w (DE-627)SPR028778073 |w (DE-600)2098765-1 |x 1477-7525 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:22 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12955-024-02241-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 22 |c 03 | ||